268 related articles for article (PubMed ID: 14998855)
21. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S; Ziras N; Vamvakas L; Varthalitis J; Papakotoulas P; Syrigos K; Vardakis N; Kalykaki A; Amarantidis K; Georgoulias V
Lung Cancer; 2006 Dec; 54(3):347-52. PubMed ID: 17030075
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
30. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in cisplatin-refractory germ cell tumor.
Chen JH; Chang PY; Yao NS
South Med J; 2009 May; 102(5):546-8. PubMed ID: 19373141
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
[TBL] [Abstract][Full Text] [Related]
34. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
38. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
[TBL] [Abstract][Full Text] [Related]
39. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
40. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A; Gutiérrez A; Palacios A; Blancas I; Navarrete M; Morey M; Perelló A; Alarcón J; Martínez J; Rodríguez J
Eur J Haematol; 2008 Feb; 80(2):127-32. PubMed ID: 18005385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]